Gilead Sciences, Inc. is a biopharmaceutical company that focuses on discovering, developing, and commercializing medicines for unmet medical needs. Its primary customers include healthcare providers and patients in the United States, Europe, and other international markets. Revenue is generated from a range of products, with significant contributions from HIV treatments (approximately 50%), liver disease therapies (around 25%), and oncology products (about 15%). The company also earns revenue from collaborations and partnerships with other pharmaceutical firms. Factors supporting Gilead's endurance include its strong pipeline of innovative therapies and established market presence, while challenges may arise from patent expirations and competition from generic drugs.
—
Gilead Sciences, Inc. is a biopharmaceutical company that focuses on discovering, developing, and commercializing medicines for unmet medical needs. Its primary customers include healthcare providers and patients in the United States, Europe, and other international markets. Revenue is generated from a range of products, with significant contributions from HIV treatments (approximately 50%), liver disease therapies (around 25%), and oncology products (about 15%). The company also earns revenue from collaborations and partnerships with other pharmaceutical firms. Factors supporting Gilead's endurance include its strong pipeline of innovative therapies and established market presence, while challenges may arise from patent expirations and competition from generic drugs.
—
Daily adjusted close
Gilead Sciences, Inc. is a biopharmaceutical company that focuses on discovering, developing, and commercializing medicines for unmet medical needs. Its primary customers include healthcare providers and patients in the United States, Europe, and other international markets. Revenue is generated from a range of products, with significant contributions from HIV treatments (approximately 50%), liver disease therapies (around 25%), and oncology products (about 15%). The company also earns revenue from collaborations and partnerships with other pharmaceutical firms. Factors supporting Gilead's endurance include its strong pipeline of innovative therapies and established market presence, while challenges may arise from patent expirations and competition from generic drugs.